Mukka Proteins board to meet on June 12 for equity fundraise after credit downgrade
The board will consider raising funds via a preferential issue, rights issue, or another mode. The move follows a CARE Ratings downgrade citing a 189-day working capital cycle.
— 1 earlier story on Mukka Proteins Ltd. →What's new
- Mukka's board will meet June 12, 2026 to consider raising equity capital.
- The company has not disclosed the size or specific instrument.
- The meeting follows a CARE Ratings downgrade that cited a 189-day working capital cycle and 95% average bank limit utilisation.
Why this matters
An equity raise is the clearest signal yet that Mukka's credit deterioration is forcing a balance-sheet fix. The lack of specifics leaves the scale of dilution unknown, but the trigger is clear: the company's liquidity is stretched, and it needs outside capital.
What we're watching
- Whether the June 12 meeting produces a concrete size and instrument choice.
- The dilution terms: a preferential issue concentrates ownership, a rights issue does not.
- CARE's next review — a successful raise could stabilise the rating outlook.
The full read
Mukka Proteins will meet on June 12 to decide how to raise new equity capital. The board hasn't picked an instrument yet; a preferential issue, a rights issue, and other modes are all on the table. The trigger is straightforward. CARE Ratings recently downgraded Mukka, citing a 189-day working capital cycle and 95% average bank limit utilisation. The company's credit profile has deteriorated, and this is the first concrete step to fix it. What remains unclear is the scale. No amount has been disclosed, which means the market can't yet gauge the dilution or the relief. For a micro-cap, that gap between announcement and detail is where the risk sits.
Questions answered
- What will the June 12 board meeting decide?
- The board will consider a proposal to raise funds by issuing new equity securities, either through a preferential issue, a rights issue, or another mode. The company has not said which type it prefers or how much it aims to raise.
- Why is Mukka raising money now?
- The fundraise follows a CARE Ratings downgrade that flagged a working capital cycle stretched to 189 days and average bank limit utilisation of 95%. The move appears aimed at addressing this liquidity stress.
- How much will the fundraise dilute existing shareholders?
- That is unknown. The company has not disclosed the size of the raise or the specific instrument. A rights issue dilutes proportionally, while a preferential issue can concentrate ownership.
- What was the credit downgrade about?
- CARE downgraded Mukka's rating, citing a sharp increase in its working capital cycle to 189 days and average bank limit utilisation of 95%, which points to tight liquidity.
Story so far
All notes on MUKKA →- 9 Jun 2026 · 5:26 PM IST Mukka Proteins board to meet on June 12 for equity fundraise after credit downgrade
- 14d ago CARE Ratings cuts Mukka Proteins' credit rating on liquidity stress